Journal of Clinical Endocrinology & Metabolism, Vol 71, 696-704, Copyright © 1990 by Endocrine Society

ARTICLES

The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women

JF Mortola and SS Yen
Department of Reproductive Medicine, School of Medicine, University of California-San Diego, La Jolla 92093.

To discern the pharmacological effects of dehydroepiandrosterone (DHEA) in older women with low endogenous DHEA and DHEA sulfate (DS), 1600 mg/day (in four divided doses) were administered orally to six postmenopausal women for 28 days in a double blind placebo-controlled cross-over study. Serum concentrations of androgens after the first 400- mg dose of DHEA increased rapidly and reached a maximum at 180-240 min, resulting in increases over baseline of 6-fold for DHEA (5.8 +/- 2.1 to 28.8 +/- 5.5 nmol/L), 12-fold for DS (3.0 +/- 1.6 to 28.2 +/- 4.6 mumol/L) and androstenedione (1.4 +/- 0.3 to 19.5 +/- 9.8 nmol/L), 2.5- fold for testosterone (0.7 +/- 0.1 to 2.2 +/- 0.6 nmol/L), and 15-fold for dihydrotestosterone (0.2 +/- 0.06 to 2.73 +/- 1.0 nmol/L), but estrone, estradiol, and sex hormone-binding globulin (SHBG) were unchanged. Assessment at weekly intervals revealed a further increase in all androgens which was maximal at 2 weeks and remained markedly elevated, although it declined somewhat by 4 weeks. The increments observed after 2 weeks of DHEA administration reached 15-fold for DHEA (71.9 +/- 14.2 nmol/L), 9-fold for testosterone (6.5 +/- 1.7 nmol/L), and 20-fold for DS (65.1 +/- 14.9 nmol/L), androstenedione (30.5 +/- 11.5 nmol/L), and dihyrotestosterone (3.8 +/- 1.5 nmol/L). Both estrone and estradiol showed a progressive increase to 2-fold the basal value at 4 weeks. Integrated SHBG and thyroid binding globulin levels decreased (P less than 0.05) during DHEA treatment. However, LH, FSH, body weight, and percent body fat, as measured by underwater weighing, were unaltered during the 4-week experiment. A marked decline of 11.3% (P less than 0.05) in serum cholesterol and 20.0% (P less than 0.05) in high density lipoprotein noted within the first week of DHEA administration persisted for the 28-day period and was accompanied by a nonsignificant downward trend in low density lipoprotein, very low density lipoprotein, and triglycerides. Peak insulin levels during the 3-h oral glucose tolerance test were significantly higher (P less than 0.05) after the 28 days of DHEA (1126 +/- 165 vs. 746 +/- 165 pmol/L) and were accompanied by a 50% increase in the integrated insulin response (P less than 0.01) without a significant change in fasting glucose insulin or glucose-6-phosphate dehydrogenase values.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				P. A. Komesaroff Unravelling the Enigma of Dehydroepiandrosterone: Moving Forward Step by Step Endocrinology, March 1, 2008; 149(3): 886 - 888. [Full Text] [PDF]

				D. Liu, M. Iruthayanathan, L. L. Homan, Y. Wang, L. Yang, Y. Wang, and J. S. Dillon Dehydroepiandrosterone Stimulates Endothelial Proliferation and Angiogenesis through Extracellular Signal-Regulated Kinase 1/2-Mediated Mechanisms Endocrinology, March 1, 2008; 149(3): 889 - 898. [Abstract] [Full Text] [PDF]

				D. Liu, H. Si, K. A. Reynolds, W. Zhen, Z. Jia, and J. S. Dillon Dehydroepiandrosterone Protects Vascular Endothelial Cells against Apoptosis through a G{alpha}i Protein-Dependent Activation of Phosphatidylinositol 3-Kinase/Akt and Regulation of Antiapoptotic Bcl-2 Expression Endocrinology, July 1, 2007; 148(7): 3068 - 3076. [Abstract] [Full Text] [PDF]

				M. Panjari and S. R. Davis DHEA therapy for women: effect on sexual function and wellbeing Hum. Reprod. Update, May 1, 2007; 13(3): 239 - 248. [Abstract] [Full Text] [PDF]

				R. Basu, C. Dalla Man, M. Campioni, A. Basu, K. S. Nair, M. D. Jensen, S. Khosla, G. Klee, G. Toffolo, C. Cobelli, et al. Two Years of Treatment With Dehydroepiandrosterone Does Not Improve Insulin Secretion, Insulin Action, or Postprandial Glucose Turnover in Elderly Men or Women Diabetes, March 1, 2007; 56(3): 753 - 766. [Abstract] [Full Text] [PDF]

				P. Kocis Prasterone Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2201 - 2210. [Abstract] [Full Text] [PDF]

				K. S. Nair, R. A. Rizza, P. O'Brien, K. Dhatariya, K. R. Short, A. Nehra, J. L. Vittone, G. G. Klee, A. Basu, R. Basu, et al. DHEA in Elderly Women and DHEA or Testosterone in Elderly Men N. Engl. J. Med., October 19, 2006; 355(16): 1647 - 1659. [Abstract] [Full Text] [PDF]

				D. Safiulina, N. Peet, E. Seppet, A. Zharkovsky, and A. Kaasik Dehydroepiandrosterone Inhibits Complex I of the Mitochondrial Respiratory Chain and is Neurotoxic In Vitro and In Vivo at High Concentrations Toxicol. Sci., October 1, 2006; 93(2): 348 - 356. [Abstract] [Full Text] [PDF]

				J. Vrbikova and D. Cibula Combined oral contraceptives in the treatment of polycystic ovary syndrome Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291. [Abstract] [Full Text] [PDF]

				K. Dhatariya, M. L. Bigelow, and K. S. Nair Effect of Dehydroepiandrosterone Replacement on Insulin Sensitivity and Lipids in Hypoadrenal Women Diabetes, March 1, 2005; 54(3): 765 - 769. [Abstract] [Full Text] [PDF]

				P. J. Schmidt, R. C. Daly, M. Bloch, M. J. Smith, M. A. Danaceau, L. Simpson St. Clair, J. H. Murphy, N. Haq, and D. R. Rubinow Dehydroepiandrosterone Monotherapy in Midlife-Onset Major and Minor Depression Arch Gen Psychiatry, February 1, 2005; 62(2): 154 - 162. [Abstract] [Full Text] [PDF]

				K.-M. Seow, C.-C. Juan, L.-Y. Wu, Y.-P. Hsu, W.-M. Yang, Y.-L. Tsai, J.-L. Hwang, and L.-T. Ho Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance Hum. Reprod., January 1, 2004; 19(1): 48 - 53. [Abstract] [Full Text] [PDF]

				H. Kawano, H. Yasue, A. Kitagawa, N. Hirai, T. Yoshida, H. Soejima, S. Miyamoto, M. Nakano, and H. Ogawa Dehydroepiandrosterone Supplementation Improves Endothelial Function and Insulin Sensitivity in Men J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3190 - 3195. [Abstract] [Full Text] [PDF]

				F. Labrie, V. Luu-The, C. Labrie, A. Belanger, J. Simard, S.-X. Lin, and G. Pelletier Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone Endocr. Rev., April 1, 2003; 24(2): 152 - 182. [Abstract] [Full Text] [PDF]

				B. Z. Leder, K. M. LeBlanc, C. Longcope, H. Lee, D. H. Catlin, and J. S. Finkelstein Effects of Oral Androstenedione Administration on Serum Testosterone and Estradiol Levels in Postmenopausal Women J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5449 - 5454. [Abstract] [Full Text] [PDF]

				G. Johannsson, P. Burman, L. Wiren, B. E. Engstrom, A. G. Nilsson, M. Ottosson, B. Jonsson, B.-A. Bengtsson, and F. A. Karlsson Low Dose Dehydroepiandrosterone Affects Behavior in Hypopituitary Androgen-Deficient Women: A Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2046 - 2052. [Abstract] [Full Text] [PDF]

				G. A. Brown, E. R. Martini, B. S. Roberts, M. D. Vukovich, and D. S. King Acute hormonal response to sublingual androstenediol intake in young men J Appl Physiol, January 1, 2002; 92(1): 142 - 146. [Abstract] [Full Text] [PDF]

				Y. Liu, J. Ding, T. L. Bush, J. C. Longenecker, F. J. Nieto, S. H. Golden, and M. Szklo Relative Androgen Excess and Increased Cardiovascular Risk after Menopause: A Hypothesized Relation Am. J. Epidemiol., September 15, 2001; 154(6): 489 - 494. [Abstract] [Full Text] [PDF]

				F. Callies, M. Fassnacht, J. C. van Vlijmen, I. Koehler, D. Huebler, M. J. Seibel, W. Arlt, and B. Allolio Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency: Effects on Body Composition, Serum Leptin, Bone Turnover, and Exercise Capacity J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1968 - 1972. [Abstract] [Full Text]

				S. Legrain, C. Massien, N. Lahlou, M. Roger, B. Debuire, B. Diquet, G. Chatellier, M. Azizi, V. Faucounau, H. Porchet, et al. Dehydroepiandrosterone Replacement Administration: Pharmacokinetic and Pharmacodynamic Studies in Healthy Elderly Subjects J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3208 - 3217. [Abstract] [Full Text]

				G. A. Bray and F. L. Greenway Current and Potential Drugs for Treatment of Obesity Endocr. Rev., December 1, 1999; 20(6): 805 - 875. [Abstract] [Full Text]

				G. A. Brown, M. D. Vukovich, R. L. Sharp, T. A. Reifenrath, K. A. Parsons, and D. S. King Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men J Appl Physiol, December 1, 1999; 87(6): 2274 - 2283. [Abstract] [Full Text] [PDF]

				K. T. Barnhart, E. Freeman, J. A. Grisso, D. J. Rader, M. Sammel, S. Kapoor, and J. E. Nestler The Effect of Deydroepiandrosterone Supplementation to Symptomatic Perimenopausal Women on Serum Endocrine Profiles, Lipid Parameters, and Health-Related Quality of Life J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3896 - 3902. [Abstract] [Full Text]

				W. Arlt, J. Haas, F. Callies, M. Reincke, D. Hübler, M. Oettel, M. Ernst, H. M. Schulte, and B. Allolio Biotransformation of Oral Dehydroepiandrosterone in Elderly Men: Significant Increase in Circulating Estrogens J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2170 - 2176. [Abstract] [Full Text]

				A. Cagnacci, A.M. Paoletti, S. Arangino, G.B. Melis, and A. Volpe Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism Hum. Reprod., April 1, 1999; 14(4): 893 - 897. [Abstract] [Full Text] [PDF]

				M. P. Diamond, D. Grainger, M. C. Diamond, R. S. Sherwin, and R. A. DeFronzo Effects of Methyltestosterone on Insulin Secretion and Sensitivity In Women J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4420 - 4425. [Abstract] [Full Text]

				J. Parasrampuria, K. Schwartz, and R. Petesch Quality Control of Dehydroepiandrosterone Dietary Supplement Products JAMA, November 11, 1998; 280(18): 1565 - 1565. [Full Text] [PDF]

				I. Heuser, M. Deuschle, P. Luppa, U. Schweiger, H. Standhardt, and B. Weber Increased Diurnal Plasma Concentrations of Dehydroepiandrosterone in Depressed Patients J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3130 - 3133. [Abstract] [Full Text]

				W. Arlt, H.-G. Justl, F. Callies, M. Reincke, D. Hübler, M. Oettel, M. Ernst, H. M. Schulte, and B. Allolio Oral Dehydroepiandrosterone for Adrenal Androgen Replacement: Pharmacokinetics and Peripheral Conversion to Androgens and Estrogens in Young Healthy Females after Dexamethasone Suppression J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1928 - 1934. [Abstract] [Full Text]

				A. M. Corbould, S. J. Judd, and R. J. Rodgers Expression of Types 1, 2, and 3 17{beta}-Hydroxysteroid Dehydrogenase in Subcutaneous Abdominal and Intra-Abdominal Adipose Tissue of Women J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 187 - 194. [Abstract] [Full Text]

				A. Dunaif Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis Endocr. Rev., December 1, 1997; 18(6): 774 - 800. [Abstract] [Full Text]

				J. Young, B. Couzinet, K. Nahoul, S. Brailly, P. Chanson, E. E. Baulieu, and G. Schaison Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2578 - 2585. [Abstract] [Full Text] [PDF]

				O. T. Wolf, O. Neumann, D. H. HELLHAMMER, A. C. Geiben, C. J. Strasburger, R. A. Dressendorfer, K.-M. Pirke, and C. Kirschbaum Effects of a Two-Week Physiological Dehydroepiandrosterone Substitution on Cognitive Performance and Well-Being in Healthy Elderly Women and Men J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2363 - 2367. [Abstract] [Full Text] [PDF]

				E. D. Schriock, C. K. Buffington, J. R. Givens, and J. E. Buster Enhanced Post-Receptor Insulin Effects in Women Following Dehydroepiandrosterone Infusion Reproductive Sciences, January 1, 1994; 1(1): 74 - 78. [Abstract] [PDF]